Avantor® Completes Acquisition of Ritter GmbH and its Affiliates
Avantor, Inc. (NYSE: AVTR) has successfully completed the acquisition of Ritter GmbH, enhancing its capabilities in clinical diagnostics and life sciences research. This strategic move integrates Ritter's liquid dispensing technology with Avantor's lab automation solutions, aiming to deliver greater value to biopharma and healthcare customers. Ritter, known for high-quality robotic and liquid handling consumables, specializes in various diagnostic applications, further bolstering Avantor's extensive portfolio. The acquisition received all necessary regulatory approvals.
- Enhancement of product offerings with Ritter's liquid dispensing platform.
- Strengthening market position in biopharma and healthcare sectors.
- Expected synergies from combining technologies for better customer service.
- None.
RADNOR, Pa., June 10, 2021 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced today it has completed its previously announced acquisition of Ritter GmbH and its affiliates.
"By combining Ritter's liquid dispensing platform for clinical diagnostic testing and life sciences research with Avantor's offerings for critical lab automation workflows and leading global customer channel, we will enhance the value we bring to our biopharma and healthcare customers," said Michael Stubblefield, President and CEO of Avantor. "We're also excited about welcoming the Ritter associates to the Avantor team and building on the connections we already share, including a strong culture of innovation and excellence, as well as a clear commitment to sustainability."
Headquartered in Schwabmünchen, Germany, Ritter is the fastest growing manufacturer of high-quality robotic and liquid handling consumables, including conductive pipette tips engineered to exacting standards. These mission-critical consumables are used in a variety of molecular screening and diagnostic applications, including real-time polymerase chain reaction (PCR), non-molecular assays such as immunoassays, emerging high throughput in vitro diagnostics (IVD) technologies including next generation sequencing, and as part of drug discovery and clinical trial testing in pharma and biotech applications.
The completion of the acquisition follows the receipt of all applicable regulatory approvals.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com.
Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our announced transaction with Ritter as well as our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "outlook," "plan," "potential," "project," "projection," "seek," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our 2020 Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the U.S. Securities and Exchange Commission ("SEC") and available in the "Investors" section of Avantor's website, ir.avantorsciences.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Avantor files with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
Media Contact
Allison Hosak
Senior Vice President, Global Communications and Brand
Avantor
+1 908-329-7281
Allison.Hosak@Avantorsciences.com
Investor Relations Contact
Tommy J. Thomas, CPA
Vice President, Investor Relations
Avantor
+1 781-375-8051
Tommy.Thomas@Avantorsciences.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/avantor-completes-acquisition-of-ritter-gmbh-and-its-affiliates-301310437.html
SOURCE Avantor and Financial News
FAQ
What is the significance of Avantor's acquisition of Ritter GmbH?
When was the acquisition of Ritter GmbH completed?
How will the acquisition impact Avantor's business?
What are Ritter GmbH's specialties?
Did Avantor receive regulatory approvals for the acquisition?
